The cloning of at least fourteen subtypes of P2 nucleotide receptors has presented a unique challenge to medicinal chemists: the design of selective agonists and antagonists for this multiplicity of receptors with few existing leads. These receptors regulate function of the central nervous system, the immune system, the cardiovascular system, and smooth muscles. Our laboratory is developing selective agonists and antagonists for these receptors, for use both as pharmcological tools for probing receptor function and as potential therapeutic agents. P2X receptors are ligand-gated ion channels. P2Y receptors are G protein coupled receptors linked to the phosphatidyl inositol pathway as second messenger. The human P2Y1 receptor as representative of the P2Y family of metabotropic purine and pyrimidine nucleotide receptors may be modeled based on a rhodopsin template, and the resulting model is highly consistent with pharmacological and mutagenesis results. Charged residues in both the transmembrane and extracellular domains and two disulfide bridges essential for receptor activation have been identified. Selective P2Y1 receptor antagonists such as the adenine nucleotide MRS 2179 (N-methyl-2'-deoxyadenosine-3',5'-bisphosphate) and it carbocyclic analogue are under development. Modeling of P2X receptors has not been achieved, since no template for the extracellular nucleotide binding region exists. Nevertheless, a selective antagonist, MRS 2220, and a potentiator, MRS 2219, of this subtype have been identified. Both are based structurally on pyridoxal-5'-phosphate antagonists (such as PPADS), for which the SAR is being examined at all of the P2 receptor subtypes. We have also synthesized nucleotides containing conformationally constrained ribose-like rings, in order to freeze a conformation that provides favorable affinity and/or selectivity at P2 receptors. A highly potent and selective antagonist of the P2Y1 suubtype has been developed using this conformational strategy (MRS 2279). This compound has been shown to inhibit the ADP-induced aggregation of platelets.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Intramural Research (Z01)
Project #
1Z01DK031116-14
Application #
6507278
Study Section
(LBC)
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2001
Total Cost
Indirect Cost
Name
U.S. National Inst Diabetes/Digst/Kidney
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kiselev, Evgeny; Balasubramanian, Ramachandran; Uliassi, Elisa et al. (2015) Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y?? receptor. Bioorg Med Chem Lett 25:4733-9
Zhang, Dandan; Gao, Zhan-Guo; Zhang, Kaihua et al. (2015) Two disparate ligand-binding sites in the human P2Y1 receptor. Nature 520:317-21
Balasubramanian, Ramachandran; Robaye, Bernard; Boeynaems, Jean-Marie et al. (2014) Enhancement of glucose uptake in mouse skeletal muscle cells and adipocytes by P2Y6 receptor agonists. PLoS One 9:e116203
Das, Arijit; Zhou, Yixing; Ivanov, Andrei A et al. (2009) Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition. Bioconjug Chem 20:1650-9
Ko, Hyojin; Carter, Rhonda L; Cosyn, Liesbet et al. (2008) Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem 16:6319-32
Shen, Jian-Bing; Cronin, Chunxia; Sonin, Dmitry et al. (2007) P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure. Am J Physiol Heart Circ Physiol 292:H1077-84
Ivanov, Andrei A; Ko, Hyojin; Cosyn, Liesbet et al. (2007) Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate. J Med Chem 50:1166-76
Ko, Hyojin; Fricks, Ingrid; Ivanov, Andrei A et al. (2007) Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor. J Med Chem 50:2030-9
Koizumi, Schuichi; Shigemoto-Mogami, Yukari; Nasu-Tada, Kaoru et al. (2007) UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 446:1091-5
Olivecrona, Goran K; Gotberg, Matthias; Harnek, Jan et al. (2007) The ADP receptor P2Y(1) mediates t-PA release in pigs during cardiac ischemia. J Thromb Thrombolysis 24:115-22

Showing the most recent 10 out of 76 publications